Cenobamate
NERVOUS SYSTEM
Also known as: ontozry, xcopri, YKP3089
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cenobamate is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2C19 Inhibitors. DrugCentral lists 2 molecular targets, including GABRA4 and GABRA6. Recorded indications include Epilepsy having focal-onset seizures and Partial seizure.
- Approval status: onp (first approved 2019 by the FDA).
- Mechanism of action: Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors.
- Molecular targets: GABRA4 and GABRA6 (2 listed in DrugCentral).
- Indications: Epilepsy having focal-onset seizures and Partial seizure.
- ATC code: N03AX25 (Other antiepileptics).
- Molecular formula: C10H10ClN5O2; molecular weight 267.67 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Epilepsy having focal-onset seizures
- Partial seizure
Contraindications (1)
- Genetic short QT syndrome
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 2B6 Inducers; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C8 Inducers; Cytochrome P450 3A Inhibitors; Cytochrome P450 3A4 Inducers; GABA A Receptor Positive Modulators; Sodium Channel Antagonists |
|---|
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit alpha-4 | GABRA4 | allosteric modulator | EC50 4.38 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | GABRA6 | allosteric modulator | EC50 4.24 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-03-26 | EMA | — | ARVELLE THERAPEUTICS NETHERLANDS B.V. | |
| 2019-11-21 | FDA | — | SK LIFE SCIENCE INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N03AX25 | NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Seizure | 1352.5 |
| Somnolence | 364.1 |
| Product dose omission issue | 308.7 |
| Drug interaction | 266.3 |
| Multiple-drug resistance | 232.9 |
| Off label use | 179.2 |
| Ataxia | 138.2 |
| Wrong technique in product usage process | 136.2 |
| Dizziness | 132.3 |
| Generalised tonic-clonic seizure | 126.1 |
| Balance disorder | 124.3 |
| Seizure cluster | 120.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Cenobamate is on its molecule page.
| Molecular formula | C10H10ClN5O2 |
|---|---|
| Molecular weight | 267.67 g/mol |
| CAS number | 913088-80-9 |
| InChIKey | GFHAXPJGXSQLPT-VIFPVBQESA-N |
| PubChem CID | 11962412 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cenobamate used for?
DrugCentral lists the following indications for Cenobamate: Epilepsy having focal-onset seizures and Partial seizure.
How does Cenobamate work?
Cenobamate is classified as Cytochrome P450 2B6 Inducers, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 2C19 Inhibitors; its molecular targets in DrugCentral include GABRA4 (allosteric modulator) and GABRA6 (allosteric modulator).
When was Cenobamate first approved?
Cenobamate was first approved by the FDA in 2019.
What is the chemical formula of Cenobamate?
Cenobamate has the molecular formula C10H10ClN5O2 and a molecular weight of 267.67 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5355 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3989949 — compound record and bioactivity
- PubChem CID 11962412 — chemical identifiers
- DrugBank DB06119 — drug record
- FDA UNII P85X70RZWS — substance identity
- DailyMed: FDA labels for Cenobamate — current prescribing information (label search)
- UniProt P48169 (GABRA4) — target protein
- UniProt Q16445 (GABRA6) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.